Portfolio News

On July 08, 2025, the new drug application (NDA) of the innovative drug Rademikibart, jointly developed by the Simcere（2096.HK） and Connect Biopharma, was accepted by the National Medical Products Administration (NMPA) for the treatment of atopic dermatitis.

Atopic dermatitis is a chronic inflammatory, recurrent skin disease characterized by dry skin, severe itching and eczema. It can also be accompanied by chronic diseases such as asthma, allergic rhinitis and insomnia, which significantly affects the quality of life of patients. It is estimated that the number of patients currently suffering from atopic dermatitis in China is about 70 million, and is still increasing.

Rademikibart is a fully human monoclonal antibody targeting IL-4Rα, a common subunit of IL-4 receptor and IL-13 eceptor. By binding with IL-4Rα, Rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the Th2 inflammatory pathway, thus achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis and asthma.